



European Society of Contraception and Reproductive Health

ESC Central Office - Opalfeneweg 3 - 1740 Ternat - Belgium

Tel. + 32 2 582 08 52 - Fax +32 2 582 55 15

info@escrh.eu - www.escrh.eu

Grant application form first half year 2013 Seeking ESC support for a PROJECT

Introduction

The ESC will provide funding to support an individual, group, institute or organisation with a project within Europe related to the aims and scope of the ESC. Examples include: research, audit, review, needs assessment.

The money **MUST** be used for a defined project within a definite time frame.

Application	Please use this application form. Note sections with a maximum word count. Forms will be returned if the word count is exceeded.
Who can apply?	Applicants must be paid-up ESC members.
Deadline	Applications period MUST be received at ESC Central office by 1 July 2013 .
Budget	25,000 euro for applications received between 1 July and 31 December. The ESC may not be in a position to fully fund all applications.

Part A Name of the applicant requesting the funding

Name of applicant	Kristina Gemzell Danielsson
Job title	Professor, Senior consultant
Address	Dept of Obstetrics and Gynecology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
Tel no.	+46851772128
E-mail	kristina.gemzell@ki.se
Date of submission of this form	June 19,2013

Part B Proposed project

Name of the person responsible for the project (If different to the person named in box A)	
Contact details of the person noted in this box B: name of person, job title, address, tel no. email	

Part C Background of the project – narrative summary

Title of the project	Post abortion contraception - Quick start of Nexplanon in medical abortion. A randomized controlled trial
Comprehensive description of the project. (Max 200 words)	
<p>Long acting reversible contraceptives (LARCs, Implants and intrauterine contraception) are the most effective methods to help women avoid a repeat unwanted pregnancy after an abortion. Insertion of LARC at surgical abortion is associated with greater use and lower rate of repeat abortions at six months follow up (FU) than requiring women to return later to get the device. However, today the clinical routine in medical abortion is to insert LARCs at the FU 2 to 3 weeks after the abortion. Frequently women choose to do part of the abortion treatment at home and do not return for FU. Thus, the possibility to "quick start" a contraceptive method in medical abortion would be a major advantage.</p> <p>In a prospective randomized controlled equivalence trial 600 women requesting medical abortion up to 9 weeks and opting for implant for post abortion contraception will be randomized to</p> <p>Group 1) Nexplanon® insertion at the time of mifepristone administration (Day 1).</p> <p>Group 2) Nexplanon® insertion according to the clinical routine at FU 2-3 weeks after mifepristone administration.</p> <p>FU will be done at 2-3 weeks after the medical abortion. Further FU will be done over telephone at 3, 6 and 12 months after the administration of mifepristone.</p>	

When would it start / finish? (Max 20 words)	
Jan 2013 - Dec 2014	
Where will it take place – country / town, establishment? (Max 20 words)	
Multicentre trial in Sweden and UK, 6 centres in Sweden and 2 centres in Scotland.	
Objectives and needs identified. (Max 20 words)	
To optimize contraception post medical abortion and reduce unwanted pregnancy	
To ensure no interaction between the gestagen and antigestagen (mifepristone).	
Sector in the area of contraception, sexual and reproductive health.	
Postabortion contraception	
Is it a 'new' project? Yes/No	yes

If extension of an existing programme, provide information on original programme (Max 50 words)	
What outcomes will be measured? List. (Max 20 words)	
(1) efficacy (=complete uterine evacuation)	
(2) rate of unplanned pregnancy up to 1 year follow up	
(3) acceptability, adverse events, bleeding etc.	
Do you foresee any reasons (political, climatic, etc) why this project may be adversely affected? (Max 20 words)	
No. All required permissions have been obtained. The project is ready to start if funded.	

Part D Financial related information

Are there other partners or organisations supporting this same project? If so, list.
--

None. Application submitted (many years ago) to MSD and Bayer to provide implants
Have you already obtained any funding towards this project? (If yes or still awaiting a response, please give details) (Max 20 words)
No
How much money are you requesting? A detailed budget must be provided. (Max 50 words)
<ul style="list-style-type: none"> • Part of salary for a research nurse 10000 • Data base and monitoring 1000 • Ethics application. clinical trial: 2000 <p>TOTAL: 13 .000 Euro The cost for drugs for medical abortion and implants will be covered by the clinic as part of the routine treatment. Even if only partly funded it would mean a lot</p>
Will this be part of a larger fund or stand alone? (Max 20 words)
Stand alone
Who will oversee the budget & keep accounts?
Controller Sandra Brogarde at the Dept of Women's and Children's Health, Karolinska Institutet

Part E Follow-up

I / We, as responsible agents for this project, agree to the following 6 points:

I/We agree that all monies will be spent appropriately	yes
I/We agree to advise you at the earliest time if this project is delayed or cannot be completed	yes
I/We agree to provide a report to the Board of Directors of the ESC within 6 months of the end of the project and yearly, if the project lasts longer than 1 year.	yes
I/We agree to present the ESC treasurer with a detailed budget at the end of the project. <i>(if the project is longer than 1 year, the funding may be awarded in stages and be dependent on appropriate reporting)</i>	yes
I/We agree that if you need to make any significant changes to the duration, contents or funding of the project after it has been awarded, I/we will advise the ESC Treasurer.	yes
I/We agree to acknowledge the ESC as a donor in any publications and oral	yes

communications resulting from this project. Ideally any manuscript should be sent to the ESC journal in the first instance.



Signed
Name Kristina Gemzell Danielsson

Date June 19, 2013

Please return this form (by email) to:

ESC Central Office
Opalfeneweg 3
B-1740 Ternat, Belgium
Tel +32 2 582 08 52
Fax +32 2 582 55 15
info@escrh.eu